GlassScriptPhysician profile
Brian J Katz
NPI 1013951755
$3,273.27
in general payments reported to CMS, 2019-2025
33 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $206 · 2021: $454 · 2022: $572 · 2023: $403 · 2024: $310 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $752.46 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $318.01 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Regeneron Healthcare Solutions, INC. | $258.13 | 2019-2025 | Dupixent, Libtayo |
| Almirall LLC | $244.54 | 2021-2025 | Klisyri, Seysara |
| Organogenesis INC. | $173.78 | 2021-2025 | Via Matrix, Puraply Wound Matrix |
| Leo Pharma INC. | $148.87 | 2019-2021 | |
| Amgen INC. | $143.70 | 2019-2020 | |
| Allergan, INC. | $143.40 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $141.72 | 2019-2023 | |
| Genzyme Corporation | $84.56 | 2019-2021 | |
| Mylan Specialty L.P. | $74.56 | 2022 | |
| Dermira, INC. | $70.66 | 2019 | |
| Pfizer INC. | $67.65 | 2021-2023 | |
| Incyte Corporation | $63.64 | 2021-2023 | Opzelura |
| Sun Pharmaceutical Industries INC. | $53.57 | 2021-2023 | Winlevi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sebela Pharmaceuticals INC. | $51.86 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $50.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $46.23 | 2022-2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $39.74 | 2023 | |
| Lilly USA, LLC | $36.42 | 2019 | |
| Janssen Biotech, INC. | $31.58 | 2020 | |
| Celgene Corporation | $30.84 | 2019 | |
| Viiv Healthcare Company | $29.92 | 2021 | |
| Smith+Nephew, INC. | $26.58 | 2022 | |
| Acera Surgical, INC. | $23.94 | 2022 | |
| Verrica Pharmaceuticals INC. | $23.83 | 2023 | Ycanth |
| Biofrontera INC. | $22.45 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Stemline Therapeutics INC. | $21.92 | 2021 | |
| Botanix Sb INC | $21.20 | 2025 | Sofdra |
| Organon LLC | $20.87 | 2025 | |
| Tempus Ai, INC | $20.86 | 2024 | Merlin Test |
| Dermavant Sciences, INC. | $20.47 | 2024 | Vtama |
| Merck Sharp & Dohme LLC | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.